OXIS International, Inc. Identifies New Biomarker For Early Detection Of Cardiovascular Disease

FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS; Nouveau Marche: OXIS) (FWB: OXI), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that it has identified a new predictive diagnostic lipoprotein biomarker that has the ability to detect early cardiovascular disease.
MORE ON THIS TOPIC